Astellas Pharma Inc. (ALPMF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Tokyo, Japan. El CEO actual es Naoki Okamura.
ALPMF tiene fecha de IPO 2010-04-26, 14,754 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $29.61B.
Astellas Pharma Inc. is a Japan-based pharmaceutical company founded in 1923 that manufactures, markets, and distributes medicines globally across oncology, urology, immunology, and infectious disease. The company's key products include XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, Myrbetriq for overactive bladder, Evrenzo for anemia in chronic kidney disease, and Prograf for transplant immunosuppression. Astellas maintains an extensive pipeline and strategic partnerships with leading institutions including Merck, Harvard University, and CytomX Therapeutics, as well as collaborations in emerging areas such as targeted radiotherapy, cell therapy, and epigenetic research. The company is headquartered in Tokyo and operates a diversified portfolio of prescription and specialty pharmaceutical products serving major markets worldwide.
